<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23418">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965613</url>
  </required_header>
  <id_info>
    <org_study_id>2013-PT025</org_study_id>
    <nct_id>NCT01965613</nct_id>
  </id_info>
  <brief_title>RA-18C3 Therapy for Subjects With Pyoderma Gangrenosum</brief_title>
  <official_title>A Phase II Open Label Study of RA-18C3 in Subjects With Pyoderma Gangrenosum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XBiotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XBiotech, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with RA-18C3 will improve wound
      healing for patients with pyoderma gangrenosum.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Physician's Global Assessment</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pyoderma Gangrenosum</condition>
  <arm_group>
    <arm_group_label>RA-18C3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA-18C3</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RA-18C3</intervention_name>
    <description>IV and Subcutaneous administration</description>
    <arm_group_label>RA-18C3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:  â‰¥18

          2. History of pyoderma gangrenosum with or without other systemic disease.

        Exclusion Criteria:

          1. Treatment with any biologicals (including intravenous immunoglobulin) or
             investigational agents within the last 4 weeks (or 5 half-lives, whichever is
             longer).

          2. Treatment with corticosteroids or cyclosporine within the last 2 weeks.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael D Stecher, M.D</last_name>
    <phone>512-386-2900</phone>
  </overall_contact>
  <location>
    <facility>
      <name>XBiotech Investigative Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>October 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pyoderma Gangrenosum</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pyoderma</mesh_term>
    <mesh_term>Pyoderma Gangrenosum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
